Professor | Senior Scientist | Deputy Coordinator of Immunology Department+61 7 3362 0385
Professor Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR). He is the Coordinator of QIMR Berghofer Centre for Immunotherapy and Vaccine Development. He holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia and was also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane. Professor Khanna is a Fellow of Australian Academy of Health and Medical Sciences.
2017-current: Senior Scientist, Tumour Immunology Laboratory, QIMR Berghofer
2012-current: Coordinator of the Centre for Immunotherapy and Vaccine Development, QIMR Berghofer
2011-current: Senior Principal Research Fellow, NHMRC
2006-2010: NHMRC Principal Research Fellow, Queensland Institute of Medical Research
2001-2005: NHMRC Senior Research Fellow, Queensland Institute of Medical Research
1997-2000: NHMRC R. Douglas Wright Fellow, Queensland Institute of Medical Research
1996: Senior Research Officer, Queensland Institute of Medical Research
1995-1996: Research Officer,Queensland Institute of Medical Research
1993-1994: UQ Postdoctoral Fellow, University of Queensland
1990-1993: Research Officer, Queensland Institute of Medical Research
The primary focus of my research group has been human immune regulation. The major goals of our laboratory are to obtain a deeper understanding of the mechanisms by which the human immune response to viral infections and human cancers may be generated, augmented and applied to the treatment of these diseases.
We have used Epstein-Barr virus-associated diseases as a model to understand how cellular immune response in humans responds to persistent viral infections. Over the last 15 years, we have successfully translated our laboratory research towards the development of novel immunotherapeutic strategies for the treatment of virus-associated cancers.
Our group has successfully completed multiple clinical trials and is currently involved in three new clinical trials which involves adoptive transfer of autologous virus-specific T cells in patients with different clinical indications (e.g. nasopharyngeal carcinoma, glioblastoma and post-transplant infectious complications). We also have a highly successful research program to develop T cell based therapeutic and prophylactic strategies for human cytomegalovirus (CMV)-associated diseases.
1990: PhD Postgraduate Institute of Medical Education and Research, India
1984: MSc Panjab University, India
1982: BSc (Medical) Panjab University, India